Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,904 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AstraZeneca Clear all
Completed Phase 2 Interventional

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

NCT00241423
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 31, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR

NCT00198159
View directory record Official record
Conditions
Refractory Germ Cell Tumors Expressing EGRF
Interventions
ZD1839 Iressa
Drug
Lead sponsor
Indiana University
Other
Eligibility
15 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

NCT01069822
View directory record Official record
Conditions
Healthy
Interventions
AZD6765, midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 31, 2026, 5:29 PM EDT
Not yet recruiting No phase listed Observational

LTFU for All Cell and Gene Therapy Studies

NCT06194461
View directory record Official record
Conditions
Hepatocellular Carcinoma, Prostate Cancer
Interventions
AZD5851, AZD0754
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 4 Interventional

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

NCT00477581
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
19
States / cities
Los Angeles, California • Spring Valley, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Not applicable Interventional Results available

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

NCT02962492
View directory record Official record
Conditions
Evaluate Ketogenic Stress
Interventions
Exenatide/Exenatide extended release, Dapagliflozin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 31, 2026, 5:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

NCT06897930
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
AZD0120, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional Results available

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

NCT04951492
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Olaparib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

NCT04610892
View directory record Official record
Conditions
Coronary Heart Disease (CHD)
Interventions
MEDI6570, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Mobile, Alabama • Beverly Hills, California • Covina, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

NCT04136171
View directory record Official record
Conditions
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions
Eplontersen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Completed No phase listed Observational

Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume

NCT04430712
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

NCT00496665
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Vandetanib, Cyclophosphamide, Methotrexate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 31, 2026, 5:29 PM EDT
Active, not recruiting Phase 1 Interventional

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

NCT04042701
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Carcinoma
Interventions
Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

NCT02179671
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Interventions
Gefitinib, AZD9291, Selumetinib+Docetaxel, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Goodyear, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 31, 2026, 5:29 PM EDT
Withdrawn Phase 2 Interventional

Naloxegol for Opioid-Related Gastroparesis

NCT03036891
View directory record Official record
Conditions
Gastroparesis, Opioid Use
Interventions
Naloxegol 25 MG Oral Tablet [Movantik], Placebo Oral Tablet
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 31, 2026, 5:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.

NCT00314210
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Quetiapine SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
56
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 31, 2026, 5:29 PM EDT
Active, not recruiting Phase 4 Interventional

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689
View directory record Official record
Conditions
Asthma
Interventions
Albuterol and budesonide inhalation aerosol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

NCT03688074
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 31, 2026, 5:29 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

NCT00227318
View directory record Official record
Conditions
Hypertension
Interventions
ATACAND
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
42
States / cities
Mobile, Alabama • Long Beach, California • Redondo Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

NCT01176097
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD5658, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

NCT02401048
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions
Ibrutinib, MEDI4736
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

NCT00885378
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin plus metformin IR, Placebo plus metformin IR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Concord, California • Fountain Valley, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 31, 2026, 5:29 PM EDT